-
公开(公告)号：US07186686B2
公开(公告)日：2007-03-06
申请号：US10431175
申请日：2003-05-06
CPC分类号： A61K9/0019 , A61K47/183 , A61K47/20 , A61K47/40 , Y10S435/808 , Y10S514/866 , Y10S530/808
摘要： A composition is disclosed that comprises a mixture of polypeptides of opposite charge and an excipient selected from the group consisting of arginine, lysine, glutamic acid, sodium dodecyl sulfate, beta-hydroxy cyclodextrin, and beta-cyclodextrin sulfobutyl ether.
摘要翻译： 公开了包含相反电荷的多肽和选自精氨酸，赖氨酸，谷氨酸，十二烷基硫酸钠，β-羟基环糊精和β-环糊精磺丁基醚的赋形剂的混合物的组合物。
-
公开(公告)号：US06559122B1
公开(公告)日：2003-05-06
申请号：US09539310
申请日：2000-03-30
IPC分类号： A61K3828
CPC分类号： A61K9/0019 , A61K47/183 , A61K47/20 , A61K47/40 , Y10S435/808 , Y10S514/866 , Y10S530/808
摘要： A composition is disclosed that comprises a mixture of polypeptides of opposite charge and an excipient selected from the group consisting of arginine, lysine, glutamic acid, sodium dodecyl sulfate, beta-hydroxy cyclodextrin, and beta-cyclodextrin sulfobutyl ether.
摘要翻译： 公开了包含相反电荷的多肽和选自精氨酸，赖氨酸，谷氨酸，十二烷基硫酸钠，β-羟基环糊精和β-环糊精磺丁基醚的赋形剂的混合物的组合物。
-
公开(公告)号：US5783556A
公开(公告)日：1998-07-21
申请号：US696314
申请日：1996-08-13
IPC分类号： A61K45/00 , A61K9/00 , A61K38/27 , A61K38/28 , A61K38/30 , A61K47/02 , A61K47/10 , A61K47/12 , A61P3/10 , A61K38/00 , A61K38/24
CPC分类号： A61K9/0019 , A61K38/30 , A61K47/12 , A61K47/02 , A61K47/10
摘要： Formulations containing NPH insulin are useful for treating hyperglycemic disorders, such as diabetes, in a mammal in need of treatment. One such formulation, which is preferably administered parenterally, more preferably by injection, comprises IGF-I and NPH insulin, in amounts of from or about 1 to 10 mg IGF-I and from or about 0.2 to 2 mg NPH insulin in a pharmaceutically acceptable carrier. Another such formulation comprises IGF-I and NPH insulin in an acetic acid salt buffer. Still another formulation comprises IGF-I and NPH insulin in a weight ratio of NPH insulin to IGF-I of from or about 10:1 to 1:50 (w/w), from or about 0.05 to 0.3M of an osmolyte, from or about 0.1 to 10 mg/mL of a stabilizer, and from or about 5 to 100 mM of a buffer at from or about pH 5 to 7. A still further composition comprises NPH insulin in an acetic acid salt buffer.
摘要翻译： 含有NPH胰岛素的制剂可用于治疗需要治疗的哺乳动物中的高血糖病症，例如糖尿病。 一种这样的制剂，其优选通过胃肠外，更优选通过注射施用，包含IGF-1和NPH胰岛素，其量为约1-10mg IGF-I和约0.2至2mg NPH胰岛素，其药学上可接受的 载体 另一种这样的制剂在乙酸盐缓冲液中包含IGF-1和NPH胰岛素。 另一制剂包含IGF-I和NPH胰岛素，NPH胰岛素与IGF-I的重量比为约10:1至1:50（w / w），或约0.05至0.3M的渗透液，来自 或约0.1至10mg / mL的稳定剂，以及约或约5至100mM的缓冲液，其pH值至约为5至7.还有一种组合物包含在乙酸盐缓冲液中的NPH胰岛素。
-
公开(公告)号：US5374620A
公开(公告)日：1994-12-20
申请号：US71818
申请日：1993-06-04
IPC分类号： A61K9/00 , A61K38/20 , A61K38/30 , A61K47/10 , A61K47/12 , A61K47/26 , A61K37/02 , A61K37/36
CPC分类号： A61K9/0019 , A61K38/27 , A61K38/30 , A61K47/10 , A61K47/12 , A61K47/26 , Y10S930/12
摘要： A combined formulation for IGF-I and growth hormone (GH) is useful for enhancing growth of a mammal. This formulation, which may be administered by infusion or injection to enhance growth, comprises IGF-I and GH, each in amounts of 0.1 to 100 mg/ml, in a pharmaceutically acceptable carrier at a pH of about 5-6 containing a surfactant, wherein the amounts of IGF-I and GH in the composition are effective to promote growth of a mammal more than an equivalent dose of IGF-I or GH alone, and wherein the weight ratio of IGF-I to GH in the composition ranges from 0.002:1 to 240:1.
摘要翻译： IGF-I和生长激素（GH）的组合制剂可用于增强哺乳动物的生长。 可以通过输注或注射来施用以增强生长的该制剂在含有表面活性剂的pH约5-6的药学上可接受的载体中包含0.1至100mg / ml的IGF-1和GH， 其中所述组合物中IGF-1和GH的量对于促进哺乳动物的生长有效地超过单独的IGF-1或GH等效剂量，并且其中组合物中IGF-1与GH的重量比为0.002 ：1〜240：1。
-
公开(公告)号：US5681814A
公开(公告)日：1997-10-28
申请号：US071819
申请日：1993-06-04
IPC分类号： A61K9/00 , A61K38/00 , A61K38/20 , A61K38/30 , A61K47/10 , A61K47/12 , A61K47/26 , C07K14/47 , C07K14/65 , G01N33/68 , A01N37/18
CPC分类号： A61K38/27 , A61K38/30 , A61K47/10 , A61K9/0019 , C07K14/4702 , G01N33/6872 , A61K47/12 , A61K47/26
摘要： A formulation for IGF-I is disclosed that is useful in treating hyperglycemic disorders and, in combination with growth hormone, in enhancing growth of a mammal. Also disclosed is a process for preparing a formulation of growth hormone and IGF-I from the IGF-I formulation. The IGF-I formulation comprises about 2-20 mg/ml of IGF-I, about 2-50 mg/ml of an osmolyte, about 1-15 mg/ml of a stabilizer, and a buffered solution at about pH 5-5.5, optionally with a surfactant.
摘要翻译： 公开了用于治疗高血糖病症和与生长激素联合用于增强哺乳动物生长的IGF-1的制剂。 还公开了从IGF-I制剂制备生长激素和IGF-I的制剂的方法。 IGF-I制剂包含约2-20mg / ml的IGF-I，约2-50mg / ml的渗透液，约1-15mg / ml的稳定剂和约pH5.5.5的缓冲溶液 ，任选地与表面活性剂。
-
公开(公告)号：US5597802A
公开(公告)日：1997-01-28
申请号：US458595
申请日：1995-06-02
IPC分类号： A61K9/00 , A61K38/00 , A61K38/20 , A61K38/30 , A61K47/10 , A61K47/12 , A61K47/26 , C07K14/47 , C07K14/65 , G01N33/68 , A61K38/27
CPC分类号： A61K38/27 , A61K38/30 , A61K47/10 , A61K9/0019 , C07K14/4702 , G01N33/6872 , A61K47/12 , A61K47/26
摘要： A formulation for IGF-I is disclosed that is useful in treating hyperglycemic disorders and, in combination with growth hormone, in enhancing growth of a mammal. Also disclosed is a process for preparing a formulation of growth hormone and IGF-I from the IGF-I formulation. The IGF-I formulation comprises about 2-20 mg/ml of IGF-I, about 2-50 mg/ml of an osmolyte, about 1-15 mg/ml of a stabilizer, and a buffered solution at about pH 5-5.5, optionally with a surfactant.
摘要翻译： 公开了用于治疗高血糖病症和与生长激素联合用于增强哺乳动物生长的IGF-1的制剂。 还公开了从IGF-I制剂制备生长激素和IGF-I的制剂的方法。 IGF-I制剂包含约2-20mg / ml的IGF-I，约2-50mg / ml的渗透液，约1-15mg / ml的稳定剂和约pH5.5.5的缓冲溶液 ，任选地与表面活性剂。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.032 秒)